In drug discovery, great science alone is not enough because commercial viability ultimately decides which programmes survive and attract partners. This Q&A explores how integrating Business Development and Licensing (BD&L) from the earliest stages can guide R&D strategy, sharpen decisions and de-risk the path to market.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

New in vivo data show a circular RNA platform can deliver up to a 50-fold increase in gene expression in the eye compared with conventional mRNA-based AAV approaches.

Promatix Biosciences Ltd has announced positive preclinical data for its first-in-class bispecific antibody–drug conjugate, PBS293-MMAE, demonstrating enhanced tumour selectivity, improved suppression and reduced toxicity in colorectal cancer models.

Scientists have discovered how tuberculosis bacteria stiffen immune cell membranes to survive inside the body, a breakthrough that could lead to the development of new TB treatments.

New research shows that lipid nanoparticles used in mRNA vaccines may deliver RNA more effectively when their structure is disorganised.

Researchers at Sultan Qaboos University have identified three antimicrobial peptides from dromedary camels that demonstrate potent activity against multidrug-resistant bacteria.

A major international study has discovered genetic similarities between cancers in cats and humans, potentially helping to inform future drugs that could benefit both species.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.